Arvinas Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$ARVN
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________
FORM 8-K
__________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2024
__________________
(Exact name of registrant as specified in its charter)
__________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||
Registrant’s telephone number, including area code: (203 ) 535-1456
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
__________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
The | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the annual meeting of stockholders of the Company held on May 29, 2024 (the “2024 Annual Meeting”), the Company’s stockholders voted on the following proposals:
1. The following nominees were elected to the Board as Class III directors for terms expiring at the 2027 annual meeting of stockholders.
For | Withheld | Broker Non-Votes | ||||||||||||||||||
| Everett Cunningham | 54,322,163 | 3,128,381 | 3,287,145 | |||||||||||||||||
Edward Kennedy Jr. | 47,979,123 | 9,471,421 | 3,287,145 | |||||||||||||||||
Briggs Morrison, M.D. | 38,515,137 | 18,935,407 | 3,287,145 | |||||||||||||||||
2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.
For: | 53,542,107 | |||||||
Against: | 3,886,277 | |||||||
Abstain: | 22,160 | |||||||
Broker Non-Votes: | 3,287,145 | |||||||
3. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024 was ratified.
For: | 60,592,542 | |||||||
Against: | 123,004 | |||||||
Abstain: | 22,143 | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ARVINAS, INC. | ||||||||
| Date: May 30, 2024 | By: | /s/ Randy Teel | ||||||
Randy Teel Interim Chief Financial Officer | ||||||||